AKR1C3 silencing inhibits autophagy-dependent glycolysis in thyroid cancer cells by inactivating ERK signaling.
Gao Y, Tao W, Wang S, Duan R, Zhang Z.

Inhibition of aldo-keto reductase 1C3 overcomes gemcitabine/cisplatin resistance in bladder cancer.
Himura R, Kawano S, Nagata Y, Kawai M, Ota A, Kudo Y, Yoshino Y, Fujimoto N, Miyamoto H, Endo S, Ikari A.

Aldo-keto reductase family member C3 (AKR1C3) promotes hepatocellular carcinoma cell growth by producing prostaglandin F2α.
Jeng KS, Cheng PY, Lin YH, Liu PC, Tseng PH, Wang YC, Chang CF, Leu CM., Free PMC Article

Keratinocytes Exposed to Blue or Red Light: Proteomic Characterization Showed Cytoplasmic Thioredoxin Reductase 1 and Aldo-Keto Reductase Family 1 Member C3 Triggered Expression.
Lazzarini R, Tartaglione MF, Ciarapica V, Piva F, Giulietti M, Fulgenzi G, Martelli M, Ledda C, Vitale E, Malavolta M, Santarelli L, Bracci M., Free PMC Article

In Vitro Evaluation of the Reductase Activities of Human AKR1C3 Allelic Variants.
Takano S, Fukami T, Ichida H, Suzuki K, Nakano M, Nakajima M.

AKR1C3 suppresses ferroptosis in hepatocellular carcinoma through regulation of YAP/SLC7A11 signaling pathway.
Chen J, Zhang J, Tian W, Ge C, Su Y, Li J, Tian H.

Establishing a Proteomics-Based Signature of AKR1C3-Related Genes for Predicting the Prognosis of Prostate Cancer.
Cui X, Li C, Ding J, Yao Z, Zhao T, Guo J, Wang Y, Li J., Free PMC Article

Availability of aldo-keto reductase 1C3 and ATP-binding cassette B1 as therapeutic targets for alleviating paclitaxel resistance in breast cancer MCF7 cells.
Matsunaga T, Horinouchi M, Saito H, Hisamatsu A, Iguchi K, Yoshino Y, Endo S, Ikari A.

Influence of aldo-keto reductase 1C3 polymorphisms in early-onset female psoriasis patients.
Nojiri Y, Nakamura M, Magara T, Yamamoto A, Ikumi K, Nakamura R, Nishida E, Haarmann-Stemmann T, Morita A., Free PMC Article

AKR1C3-dependent lipid droplet formation confers hepatocellular carcinoma cell adaptability to targeted therapy.
Wu C, Dai C, Li X, Sun M, Chu H, Xuan Q, Yin Y, Fang C, Yang F, Jiang Z, Lv Q, He K, Qu Y, Zhao B, Cai K, Zhang S, Sun R, Xu G, Zhang L, Sun S, Liu Y., Free PMC Article

Plasma Exosomal AKR1C3 mRNA Expression Is a Predictive and Prognostic Biomarker in Patients with Metastatic Castration-Resistant Prostate Cancer.
Zhu S, Ni Y, Wang Z, Zhang X, Zhang Y, Zhao F, Dai J, Wang Z, Zhu X, Chen J, Zhao J, Zeng Y, Chen N, Zeng P, Shen P, Sun G, Zeng H., Free PMC Article

AKR1C3 decreased CML sensitivity to Imatinib in bone marrow microenvironment via dysregulation of miR-379-5p.
Pan D, Yang W, Zeng Y, Li W, Wang K, Zhao L, Li J, Ye Y, Guo Q.

Characterization of the major single nucleotide polymorphic variants of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase).
Detlefsen AJ, Wangtrakuldee P, Penning TM., Free PMC Article

ARID3A promotes the chemosensitivity of colon cancer by inhibiting AKR1C3.
Li Y, Tang J, Li J, Du Y, Bai F, Yang L, Li X, Jin X, Wang T.

Assessment of factors associated with PSA level in prostate cancer cases and controls from three geographical regions.
Karunasinghe N, Minas TZ, Bao BY, Lee A, Wang A, Zhu S, Masters J, Goudie M, Huang SP, Jenkins FJ, Ferguson LR., Free PMC Article

Development of cisplatin resistance in breast cancer MCF7 cells by up-regulating aldo-keto reductase 1C3 expression, glutathione synthesis and proteasomal proteolysis.
Kobayashi M, Yonezawa A, Takasawa H, Nagao Y, Iguchi K, Endo S, Ikari A, Matsunaga T.

Transcriptomic Profiling Reveals AKR1C1 and AKR1C3 Mediate Cisplatin Resistance in Signet Ring Cell Gastric Carcinoma via Autophagic Cell Death.
Phoo NLL, Dejkriengkraikul P, Khaw-On P, Yodkeeree S., Free PMC Article

AKR1C2 and AKR1C3 expression in adipose tissue: Association with body fat distribution and regulatory variants.
Ostinelli G, Vijay J, Vohl MC, Grundberg E, Tchernof A., Free PMC Article

AKR1C3 is a biomarker and druggable target for oropharyngeal tumors.
Peraldo-Neia C, Ostano P, Mello-Grand M, Guana F, Gregnanin I, Boschi D, Oliaro-Bosso S, Pippione AC, Carenzo A, De Cecco L, Cavalieri S, Micali A, Perrone F, Averono G, Bagnasacco P, Dosdegani R, Masini L, Krengli M, Aluffi-Valletti P, Valente G, Chiorino G.

Diagnostic and prognostic values of AKR1C3 and AKR1D1 in hepatocellular carcinoma.
Zhu P, Feng R, Lu X, Liao Y, Du Z, Zhai W, Chen K., Free PMC Article

Microproteomics and Immunohistochemistry Reveal Differences in Aldo-Keto Reductase Family 1 Member C3 in Tissue Specimens of Ulcerative Colitis and Crohn's Disease.
Arafah K, Kriegsmann M, Renner M, Lasitschka F, Fresnais M, Kriegsmann K, von Winterfeld M, Goeppert B, Kriegsmann J, Casadonte R, Kazdal D, Bulet P, Longuespée R.

A Positive Feedback Loop of AKR1C3-Mediated Activation of NF-κB and STAT3 Facilitates Proliferation and Metastasis in Hepatocellular Carcinoma.
Zhou Q, Tian W, Jiang Z, Huang T, Ge C, Liu T, Zhao F, Chen T, Cui Y, Li H, Yao M, Li J, Tian H.

The AKR1C3/AR-V7 complex maintains CRPC tumour growth by repressing B4GALT1 expression.
Wang B, Wu S, Fang Y, Sun G, He D, Hsieh JT, Wang X, Zeng H, Wu K., Free PMC Article

AKR1C3 mediates pan-AR antagonist resistance in castration-resistant prostate cancer.
Hertzog JR, Zhang Z, Bignan G, Connolly PJ, Heindl JE, Janetopoulos CJ, Rupnow BA, McDevitt TM.

Significance of aldo-keto reductase 1C3 and ATP-binding cassette transporter B1 in gain of irinotecan resistance in colon cancer cells.
Matsunaga T, Okumura N, Saito H, Morikawa Y, Suenami K, Hisamatsu A, Endo S, Ikari A.